Loading...
Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application.
Nnamani, Petra O Hansen, Steffi Windbergs, Maike Lehr, Claus-Michael
Nnamani, Petra O
Hansen, Steffi
Windbergs, Maike
Lehr, Claus-Michael
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2014-12-30
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 322.27 KB
Loading...
figures
Adobe PDF, 1.78 MB
Loading...
tables
Adobe PDF, 309.05 KB
Other Titles
Abstract
NLC topical formulation as an alternative to oral and parenteral (IM) delivery of artemether (ART), a poorly water-soluble drug was designed. A Phospholipon 85G-modified Gelucire 43/01 based NLC formulation containing 75% Transcutol was chosen from DSC studies and loaded with gradient concentration of ART (100-750mg). ART-loaded NLCs were stable (-22 to -40mV), polydispersed (0.4-0.7) with d90 size distribution range of 247-530nm without microparticles up to one month of storage. The encapsulation efficiency (EE%) for ART in the NLC was concentration independent as 250mg of ART loading achieved ∼61%. DSC confirmed molecular dispersion of ART due to low matrix crystallinity (0.028J/g). Ex vivo study showed detectable ART amounts after 20h which gradually increased over 48h achieving ∼26% cumulative amount permeated irrespective of the applied dose. This proves that ART permeates excised human epidermis, where the current formulation served as a reservoir to gradually control drug release over an extended period of time. Full thickness skin study therefore may confirm if this is a positive signal to hope for a topical delivery system of ART.
Citation
Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application. 2014, 477 (1-2):208-17 Int J Pharm
Affiliation
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1873-3476